The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome.
Uzun
Mehmet
M
Yiğiner
Omer
O
Kirilmaz
Ata
A
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000069059:Atorvastatin; D000075202:Contraindications; D003324:Coronary Artery Disease / Q000150:complications* / Q000188:drug therapy*; D005234:Fatty Liver / Q000150:complications* / Q000188:drug therapy; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications*; D011758:Pyrroles / Q000627:therapeutic use*
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D000410:Alanine Transaminase